0001727689-24-000082.txt : 20240712 0001727689-24-000082.hdr.sgml : 20240712 20240712115310 ACCESSION NUMBER: 0001727689-24-000082 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240712 DATE AS OF CHANGE: 20240712 EFFECTIVENESS DATE: 20240712 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioVaxys Technology Corp. CENTRAL INDEX KEY: 0001882559 ORGANIZATION NAME: IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-518554 FILM NUMBER: 241113716 BUSINESS ADDRESS: STREET 1: 146 THIRTIETH STREET, SUITE 100 CITY: ETOBICOKE STATE: A6 ZIP: M8W 3D4 BUSINESS PHONE: 646-452-7054 MAIL ADDRESS: STREET 1: 146 THIRTIETH STREET, SUITE 100 CITY: ETOBICOKE STATE: A6 ZIP: M8W 3D4 D 1 primary_doc.xml X0708 D LIVE 0001882559 BioVaxys Technology Corp. 146 THIRTIETH STREET, SUITE 100 ETOBICOKE A6 ONTARIO, CANADA M8W 3D4 646-452-7054 BRITISH COLUMBIA, CANADA Lions Bay Mining Corp. None Corporation true James Passin 146 Thirtieth Street, Suite 100 Etobicoke A6 ONTARIO, CANADA M8W 3D4 Executive Officer Director Anthony Dutton 146 Thirtieth Street, Suite 100 Etobicoke A6 ONTARIO, CANADA M8W 3D4 Director Craig Loverock 146 Thirtieth Street, Suite 100 Etobicoke A6 ONTARIO, CANADA M8W 3D4 Director Christopher Cherry 146 Thirtieth Street, Suite 100 Etobicoke A6 ONTARIO, CANADA M8W 3D4 Executive Officer Kenneth Kovan 146 Thirtieth Street, Suite 100 Etobicoke A6 ONTARIO, CANADA M8W 3D4 Executive Officer David Berd 146 Thirtieth Street, Suite 100 Etobicoke A6 ONTARIO, CANADA M8W 3D4 Executive Officer Biotechnology No Revenues 06b false 2024-05-10 true true true true true Units, each comprised of one common share and one common share purchase warrant having an exercise price of C$0.15 and a term of 24 months false 0 173071 52324 120747 Dollar amounts have been converted from Canadian dollars using the 0.7318 Bank of Canada daily exchange rate on 5-10-24. Total Remaining to be Sold represents the aggregate exercise price of all warrants sold in the United States. false 1 0 0 0 true A portion of the net proceeds may be used for general working capital purposes, including for payments to officers and directors in the ordinary course, but proceeds are not earmarked for such payments false BioVaxys Technology Corp. /s/ Christopher Cherry Christopher Cherry Chief Financial Officer 2024-07-11